CRL vs SNY
Charles River Laboratories vs Sanofi — AI-powered side-by-side comparison
CRL
Charles River Laboratories
61
Buy
VS
| Metric | CRL | SNY |
|---|
| AI Score |
61
|
66
|
| Price |
$297.55
|
$46.00
|
| P/E Ratio |
-61.69×
|
24.00×
|
| ROE |
-4.6%
|
10.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
32.2%
|
72.8%
|
| Debt / Equity |
1.07×
|
0.34×
|
| Dividend Yield |
0.0%
|
5.3%
|
| RSI (14) |
79.8
|
67.8
|
| Beta |
1.376
|
0.278
|
| Expected Upside |
+1.4%
|
+6.4%
|
AI Committee View
Current Innellis committee reasoning for CRL versus SNY.
SNY leads by 5 points.
SNY scores 66/100 (Buy) versus CRL at 61/100 (Buy).
CRL Committee View
80% agreement
5 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — 5 consecutive earnings beats -- consistent execution. Risk Analyst remains cautious — bollinger bandwidth of 35.8% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- RSI at 80 is in overbought territory — Technical
- Weekly RSI at 87 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 35.8% signals elevated volatility — Risk
SNY Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.28) -- balance sheet can absorb a shock. The main limiting factor is eps declining -37.4% yoy despite any revenue growth. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- Dividend yield of 4.1% pays you to wait — Value
- Revenue growing 39.5% YoY -- genuine top-line momentum — Growth
Bear Case
- EPS declining -37.4% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth